Compare WNC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WNC | LRMR |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.2M | 455.8M |
| IPO Year | 2009 | 2014 |
| Metric | WNC | LRMR |
|---|---|---|
| Price | $9.12 | $4.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $11.00 | ★ $16.50 |
| AVG Volume (30 Days) | 468.5K | ★ 1.7M |
| Earning Date | 05-01-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | ★ 179.22 | N/A |
| EPS | ★ 5.07 | N/A |
| Revenue | ★ $2,027,489,000.00 | N/A |
| Revenue This Year | $10.65 | N/A |
| Revenue Next Year | $14.06 | $1,816.14 |
| P/E Ratio | $1.80 | ★ N/A |
| Revenue Growth | ★ 8.81 | N/A |
| 52 Week Low | $6.78 | $1.73 |
| 52 Week High | $12.94 | $6.42 |
| Indicator | WNC | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 53.86 |
| Support Level | $8.58 | $3.14 |
| Resistance Level | $9.33 | $5.37 |
| Average True Range (ATR) | 0.37 | 0.30 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 77.52 | 60.09 |
Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.